Publications by authors named "A K Mezochow"
Universal cytomegalovirus (CMV) prophylaxis is recommended for at-risk lung transplant recipients. Valganciclovir is currently the preferred first-line agent. Valganciclovir-related myelosuppression, however, can lead to drug discontinuation or reduction in anti-metabolite immunosuppression.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to create a Hepatotoxicity Score to better evaluate the safety of medications affecting the liver, considering the challenge posed by the simultaneous use of other harmful drugs.
- Researchers analyzed data from the Veterans Health Administration from 2000 to 2021, focusing on 193 medications linked to liver issues and monitoring hospitalization rates for severe liver injuries.
- Results showed that adjusting for the Hepatotoxicity Score altered the perceived risks of specific drugs like lansoprazole and pantoprazole when compared to omeprazole, suggesting the score can help clarify drug safety in real-world scenarios.
Importance: Current approaches to classify the hepatotoxic potential of medications are based on cumulative case reports of acute liver injury (ALI), which do not consider the size of the exposed population. There is little evidence from real-world data (data relating to patient health status and/or the delivery of health care routinely collected from sources outside of a research setting) on incidence rates of severe ALI after initiation of medications, accounting for duration of exposure.
Objective: To identify the most potentially hepatotoxic medications based on real-world incidence rates of severe ALI and to examine how these rates compare with categorization based on case reports.
Background: Opportunistic infections (OIs) are a significant cause of morbidity and mortality after organ transplantation, though data in the liver transplant (LT) population are limited.
Methods: We performed a retrospective cohort study of LT recipients between January 1, 2007 and Deceber 31, 2016 using Medicare claims data linked to the Organ Procurement and Transplantation Network database. Multivariable Cox regression models evaluated factors independently associated with hospitalizations for early (≤1 year post transplant) and late (>1 year) OIs, with a particular focus on immunosuppression.
COVID-19 in organ donors: An organ procurement organization perspective.
Transpl Infect Dis
April 2024
Background: The COVID-19 pandemic presented a significant challenge for Organ Procurement Organizations (OPOs) with the use of SARS-CoV-2 positive donors varying widely. This study used detailed single OPO data to determine the success of using SARS-CoV-2 positive donors.
Methods: We performed a retrospective cohort study including all SARS-CoV-2 positive donors referred to the Gift of Life OPO from January 1, 2021, to June 30, 2023.